UBS Initiates Coverage On SI-BONE with Buy Rating, Announces Price Target of $24
SI-BONE Inc SIBN
$17.76
▼ -1.28%
($-0.23)
📅 Earnings This Week
Open
$17.90
Prev Close
$17.99
Day Range
$17.50 – $18.27
52W Range
$11.48 – $21.89
Market Cap
$787.64M
Beta
0.71
EPS (TTM)
$-0.39
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-10-17 |
| Shares Out. | 44,350,000 |
| Website | si-bone.com/ ↗ |
| Phone | 14082070700 |
| Employees | 376 |
| Revenue | $52.6M |
| Gross Profit | $41.9M |
| Net Income | -$4.3M |
| Free Cash Flow | -$5.5M |
| Total Assets | $242.7M |
| Total Liabilities | $63.8M |
| Equity | $178.9M |
About SI-BONE Inc
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
SI-BONE Inc is a publicly traded company under the ticker symbol SIBN on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-07-01)